Global Personalized Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts

Publisher Name :
Date: 01-Apr-2017
No. of pages: 1000
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Personalized Medicine Partnering 2010-2017 report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest Personalized Medicine agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Personalized Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Personalized Medicine partnering deals.

The report presents financial deal term values for Personalized Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Personalized Medicine partnering field; both the leading deal values and most active Personalized Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1,370 online deal records of actual Personalized Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Personalized Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Personalized Medicine partnering deals signed and announced since Jan 2010. The chapter is organized by specific Personalized Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Personalized Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine technologies and products.

Key benefits

Global Personalized Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Personalized Medicine deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of Personalized Medicine agreements with numerous real life case studies

Detailed access to actual Personalized Medicine contracts entered into by leading biopharma companies

Identify most active Personalized Medicine dealmakers since 2010

Insight into terms included in a Personalized Medicine partnering agreement, with real world examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Personalized Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Personalized Medicine trends and structure of deals entered into by leading companies worldwide.

Personalized Medicine Partnering Terms and Agreements includes:

Trends in Personalized Medicine dealmaking in the biopharma industry since 2010

Analysis of Personalized Medicine deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life Personalized Medicine deals

Access to Personalized Medicine contract documents

Leading Personalized Medicine deals by value since 2010

Most active Personalized Medicine dealmakers since 2010

In Global Personalized Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Personalized Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,370 Personalized Medicine deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Personalized Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts

Table of Contents
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Personalized Medicine dealmaking
2.1. Introduction
2.2. Personalized Medicine partnering over the years
2.3. Most active Personalized Medicine dealmakers
2.4. Personalized Medicine partnering by deal type
2.5. Personalized Medicine partnering by therapy area
2.6. Deal terms for Personalized Medicine partnering
2.6.1 Personalized Medicine partnering headline values
2.6.2 Personalized Medicine deal upfront payments7
2.6.3 Personalized Medicine deal milestone payments
2.6.4 Personalized Medicine royalty rates

Chapter 3 - Leading Personalized Medicine deals
3.1. Introduction
3.2. Top Personalized Medicine deals by value

Chapter 4 - Most active Personalized Medicine dealmakers
4.1. Introduction
4.2. Most active Personalized Medicine dealmakers
4.3. Most active Personalized Medicine partnering company profiles

Chapter 5 - Personalized Medicine contracts dealmaking directory
5.1. Introduction
5.2. Personalized Medicine contracts dealmaking directory

Chapter 6 - Personalized Medicine dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Personalized Medicine deals by company A-Z
Appendix 2 - Personalized Medicine deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Personalized Medicine deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 4 - Personalized Medicine deals by therapy area
Appendix 5 -Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Personalized Medicine partnering since 2010
Figure 2: Active Personalized Medicine dealmaking activity since 2010
Figure 3: Personalized Medicine partnering by deal type since 2010
Figure 4: Personalized Medicine partnering by disease type since 2010
Figure 5: Personalized Medicine deals with a headline value
Figure 6: Personalized Medicine deals with an upfront value
Figure 7: Personalized Medicine deals with a milestone value
Figure 8: Personalized Medicine deals with a royalty rate value
Figure 9: Top Personalized Medicine deals by value since 2010
Figure 10: Most active Personalized Medicine dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • Asia-Pacific Procalcitonin (CAS 56645-65-9) Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 27-Jun-2017        Price: US 4480 Onwards        Pages: 116
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. Scope of the Report: This report focuses on the Procalcitonin (CAS 56645-65-9) in Asia-Pacific mar......
  • Europe Hyoscine-N-Butyl Bromide Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 27-Jun-2017        Price: US 4480 Onwards        Pages: 118
    Hyoscine-N-Butyl Bromideis obtained from a species of the plant genus Duboisia. It is mainly classified as an antispasmodic, which means that it is a drug used to suppress of muscle spasms, or involuntary contractions. Scope of the Report: This report focuses on the Hyoscine-N-Butyl Bromide in Europe market, especially in Germany, UK, France, Russia, and Italy. This report categorizes the market based on manufacturers, countries, type and application. Market ......
  • Europe Medical Grade Hydrogel Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 27-Jun-2017        Price: US 4480 Onwards        Pages: 117
    Hydrogel is gel-like or colloidal substances made of water and solids. Hydrogels are highly absorbent (they can contain over 90% water) natural or synthetic polymeric networks. It is widely used in medical fields, industrial fields, consumer goods etc. Scope of the Report: This report focuses on the Medical Grade Hydrogel in Europe market, especially in Germany, UK, France, Russia, and Italy. This report categorizes the market based on manufacturers, countries, type and app......
  • Global Pneumonia Vaccine Market Research Report 2017
    Published: 27-Jun-2017        Price: US 2900 Onwards        Pages: 109
    In this report, the global Pneumonia Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Pneumonia Vaccine in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China -......
  • EMEA (Europe, Middle East and Africa) Zika Virus Market Report 2017
    Published: 27-Jun-2017        Price: US 4000 Onwards        Pages: 102
    In this report, the EMEA Zika Virus market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Zika Virus for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benelux; - Middle E......
  • Asia-Pacific Rabies Vaccine Market Report 2017
    Published: 27-Jun-2017        Price: US 4000 Onwards        Pages: 108
    In this report, the Asia-Pacific Rabies Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K Doses), revenue (Million USD), market share and growth rate of Rabies Vaccine for these regions, from 2012 to 2022 (forecast), including - China - Japan - South Korea - Ta......
  • Asia-Pacific Organ Transplant Immunosuppressant Drugs Market Report 2017
    Published: 26-Jun-2017        Price: US 4000 Onwards        Pages: 126
    In this report, the Asia-Pacific Organ Transplant Immunosuppressant Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Organ Transplant Immunosuppressant Drugs for these regions, from 2012 to 2022 (forecast), including - Chi......
  • EMEA (Europe, Middle East and Africa) Anthrax Vaccines Market Report 2017
    Published: 26-Jun-2017        Price: US 4000 Onwards        Pages: 125
    In this report, the EMEA Anthrax Vaccines market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Anthrax Vaccines for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benelux; ......
  • Asia-Pacific Povidone Iodine (PVP-I) Market Report 2017
    Published: 26-Jun-2017        Price: US 4000 Onwards        Pages: 116
    In this report, the Asia-Pacific Povidone Iodine (PVP-I) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Povidone Iodine (PVP-I) for these regions, from 2012 to 2022 (forecast), including - China - Japan - South Ko......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs